Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Armaganijan Luciana V.; Alexander Karen P.; Huang Zhen; Tricoci Pierluigi; Held Claes; Van de Werf Frans; Armstrong Paul W.; Aylward Philip E.; White Harvey D.; Moliterno David J.; Wallentin Lars; Chen Edmond; Harrington Robert A.; Strony John; Mahaffey Kenneth W.; Lopes Renato D.

首页> 外文期刊>The American heart journal >Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

【24h】

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

机译：年龄对非ST段抬高急性冠状动脉综合征患者伏欧氏瘤患者的疗效和安全性的影响：缩小冠状动脉综合征（Tracer）试验中血栓受体拮抗剂对临床事件减少的识别

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Antithrombotic therapy plays an important role in the treatment of non-ST-segment elevation acute coronary syndromes (NSTE ACS) but is associated with bleeding risk. Advanced age may modify the relationship between efficacy and safety.

机译：背景技术抗血栓疗法在治疗非ST段升高急性冠状动脉综合征（NSTE ACS）中起重要作用，但与出血风险有关。高级年龄可能会修改有效性和安全之间的关系。

著录项

来源
《The American heart journal 》 |2016年第2016期| 共9页
作者
Armaganijan Luciana V.; Alexander Karen P.; Huang Zhen; Tricoci Pierluigi; Held Claes; Van de Werf Frans; Armstrong Paul W.; Aylward Philip E.; White Harvey D.; Moliterno David J.; Wallentin Lars; Chen Edmond; Harrington Robert A.; Strony John; Mahaffey Kenneth W.; Lopes Renato D.;
展开▼
作者单位

Brazilian Clin Res Inst Sao Paulo Brazil;

Duke Clin Res Inst Durham NC USA;

Duke Clin Res Inst Durham NC USA;

Duke Clin Res Inst Durham NC USA;

Uppsala Univ Dept Med Sci Cardiol Uppsala Sweden;

Univ Hosp Leuven Dept Cardiol Leuven Belgium;

Univ Alberta Edmonton AB Canada;

Flinders Univ &

Med Ctr South Australian Hlth &

Med Res Inst Adelaide SA Australia;

Green Lane Cardiovasc Serv Auckland New Zealand;

Gill Heart Inst Lexington KY USA;

Uppsala Univ Dept Med Sci Cardiol Uppsala Sweden;

Bayer HealthCare Pharmaceut Inc Whippany NJ USA;

Stanford Univ Dept Med Stanford CA 94305 USA;

Johnson &

Johnson New Brunswick NJ USA;

Stanford Univ Dept Med Stanford CA 94305 USA;

Duke Clin Res Inst Durham NC USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病 ;
关键词

相似文献

外文文献
中文文献
专利

1. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial [J] . Armaganijan Luciana V., Alexander Karen P., Huang Zhen, The American heart journal . 2016 ,第期

机译：年龄对非ST段抬高急性冠状动脉综合征患者伏欧氏瘤患者的疗效和安全性的影响：缩小冠状动脉综合征（Tracer）试验中血栓受体拮抗剂对临床事件减少的识别
2. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial [J] . Tricoci Pierluigi, Lokhnygina Yuliya, Huang Zhen, The American heart journal . 2014 ,第6期

机译：非ST段抬高急性冠状动脉综合征的vorapaxar
3. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: Subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) [J] . WhellanD.J., TricociP., ChenE., Journal of the American College of Cardiology . 2014 ,第11期

机译：接受冠状动脉搭桥手术的急性冠状动脉综合征患者的Vorapaxar：TRACER试验的亚组分析（用于急性冠脉综合征的临床事件减少的凝血酶受体拮抗剂）
4. The effect of solar-geomagnetic activity during and after hospital admission on coronary events within one year in patients with acute coronary syndromes [C] . Jone Vencloviene, Ruta Babarskiene, Irena Milvidaite, Annual conference of the International Society of Exposure Science . 2014

机译：急性冠脉综合征患者入院期间和入院后太阳地磁活动对一年内冠状动脉事件的影响
5. Clarifying the Optimal Management Strategy for Patients with Possible Acute Coronary Syndrome with Intermediate Stenosis and High-Risk Plaque Morphology on Coronary Computed Tomographic Angiography [D] . Dwyer, Stephanie M. 2019

机译：明确可能的急性冠脉综合征合并中度狭窄和高风险斑块形态的冠状动脉计算机断层扫描血管造影的最佳管理策略
6. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial [O] . Marco Valgimigli, Francesco Costa, Yuliya Lokhnygina, -1

机译：急性冠状动脉综合征后心肌梗塞与出血类型之间的权衡：凝血酶受体拮抗剂在急性冠状动脉综合征临床事件减少中的经验教训（TRACER）随机试验
7. Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery Subgroup Analysis From the TRACER Trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) [O] . Whellan David J., Tricoci Pierluigi, Chen Edmond, 2014

机译：TRACER试验中接受冠状动脉旁路移植手术的急性冠状动脉综合征患者中的Vorapaxar（凝血酶受体拮抗剂用于减少急性冠状动脉综合征的临床事件）

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

摘要

著录项

相似文献

相关主题

期刊订阅